Company Quick10K Filing
Processa Pharmaceuticals
10-Q 2020-03-31 Filed 2020-05-15
10-K 2019-12-31 Filed 2020-03-06
S-1 2019-12-13 Public Filing
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-14
10-Q 2019-03-31 Filed 2019-05-14
10-K 2018-12-31 Filed 2019-03-28
10-Q 2018-09-30 Filed 2018-11-14
S-1 2018-07-30 Public Filing
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-21
10-K 2017-12-31 Filed 2018-04-16
10-Q 2017-09-30 Filed 2017-11-20
10-Q 2017-06-30 Filed 2017-10-04
10-Q 2017-03-31 Filed 2017-10-04
10-K 2016-12-31 Filed 2017-09-25
10-Q 2016-09-30 Filed 2017-09-08
10-Q 2016-06-30 Filed 2017-08-30
10-Q 2016-03-31 Filed 2017-08-07
10-K 2015-12-31 Filed 2017-06-19
10-Q 2015-09-30 Filed 2015-12-01
10-Q 2015-06-30 Filed 2015-08-19
10-Q 2015-03-31 Filed 2015-05-15
10-K 2014-12-31 Filed 2015-04-14
10-Q 2014-09-30 Filed 2014-11-13
10-Q 2014-06-30 Filed 2014-08-19
10-Q 2014-03-31 Filed 2014-05-14
10-K 2013-12-31 Filed 2014-03-27
10-Q 2013-09-30 Filed 2013-11-08
10-Q 2013-06-30 Filed 2013-08-08
8-K 2020-03-30 Other Events, Exhibits
8-K 2020-03-17 Other Events, Exhibits
8-K 2020-03-05 Other Events, Exhibits
8-K 2020-02-25 Other Events
8-K 2020-02-13 Regulation FD, Exhibits
8-K 2020-01-14 Regulation FD, Exhibits
8-K 2019-12-19 Shareholder Rights, Amend Bylaw, Other Events, Exhibits
8-K 2019-10-23
8-K 2019-09-20 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2019-09-04 Enter Agreement, Exhibits
8-K 2019-06-19 Officers, Shareholder Vote, Exhibits
8-K 2019-06-07 Regulation FD
8-K 2019-03-13 Regulation FD
8-K 2019-02-25 Regulation FD
8-K 2019-01-09 Other Events, Exhibits
8-K 2018-12-06 Other Events
8-K 2018-10-02 Other Events, Exhibits
8-K 2018-09-05 Officers, Exhibits
8-K 2018-06-29
8-K 2018-06-04 Regulation FD
8-K 2018-05-25
8-K 2018-03-19 Enter Agreement, M&A, Exhibits

Processa Pharmaceuticals Financials

PCSA Metrics, Comps, Filings

Quarterly | Annual

Business

Processa is an emerging pharmaceutical company focused on the clinical development of drug products that are intended to improve the survival and/or quality of life for patients who have a high unmet medical need. Within this group of pharmaceutical products, we currently are developing one product for multiple indications (i.e., the use of a drug to treat a particular disease) and searching for additional products for our portfolio.

(i) to identify drugs that have potential efficacy in patients with an unmet medical need, as demonstrated by some clinical evidence, including published case studies or clinical experience, such that the patient's survival and/or quality of life might improve, (ii) to identify drug products that have been developed or approved for other indications but can be repurposed to treat those patients who have an unmet medical need, and (iii) to identify drugs that can be quickly developed within 2-4 years to completion of a pivotal study for the submission of a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) or to license the drug to a potential strategic partner just prior to a more expensive and time-consuming pivotal study.

While time to develop a drug from finding/designing a molecule (i.e., the discovery stage) to FDA approval typically takes between 10-15 years, our business model is to identify drugs that are in the clinical stage of drug development where (i) a pivotal study can be completed in 2 to 4 years or (ii) enough clinical data can be obtained to demonstrate the value of the asset to a future licensing partner. The FDA approval of the drug would then occur after the preparation of the NDA documents and the FDA review process.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Juniata Valley Financial (JUVF) 102,429 13.6 1% 667,107 593,321 0 0 5,568 9,850 134,126
F&M Bank (FMBM) 102,135 16.1 0% 813,237 722,344 0 0 2,734 8,653 139,285
Invesco CurrencyShares Australian Dollar Trust (FXA) 100,780 0% -56.1 1% 97,821 32 1,223 0 788 788 -44,220
Zoned Properties (ZDPY) 100,699 0% 277.2 0% 8,204 2,225 941 0 7 368 102,125
Virginia National Bankshares (VABK) 99,658 7.1 1% 660,790 585,236 0 0 5,258 10,047 71,803
Juniper Pharmaceuticals (JNP) 98,834 41% 49.7 -1% 67,768 19,275 55,610 22,712 -985 1,629 80,918
Hash Labs (HLAB) 98,593 -24.3 -2,247% 181 419 0 0 -4,067 -4,048 98,439
Nuvera Communications (NUVR) 98,504 0% 7.1 4% 164,114 84,747 48,592 0 6,727 21,163 151,275
ITUS (ITUS) 98,193 0% -9.7 -142% 6,843 1,044 250 0 -9,708 -9,689 93,796
Capital Properties (CPTP) 97,349 0% 30.3 23% 9,785 1,837 3,907 0 2,261 3,127 94,790
Processa Pharmaceuticals (PCSA) 96,996 -40.0 -24% 10,821 2,151 0 0 -2,583 -2,410 96,491
Addentax Group (ATXG) 96,315 14% -113.5 -15% 5,879 8,162 9,240 1,309 -855 -847 96,046
Eaco (EACO) 95,530 28% 6.2 10% 88,765 40,144 215,534 60,071 9,012 14,872 92,780
Cortland Bancorp (CLDB) 95,237 7.1 1% 700,621 626,468 0 0 5,378 10,511 74,729
ChoiceOne Financial Services (COFS) 94,691 0% 8.1 1% 663,589 578,963 3,629 0 5,973 9,668 78,117
Aerkomm (AKOM) 94,280 1% -11.7 -17% 51,277 3,924 1,600 13 -8,941 -7,810 91,529
Invuity (IVTY) 92,683 67% -2.9 -75% 48,729 46,397 40,834 27,211 -36,461 -31,788 93,415
First National (FXNC) 92,475 0% 5.0 1% 777,193 701,877 5,726 0 6,840 12,425 62,102
Nobility Homes (NOBH) 92,404 28% 9.0 11% 55,980 7,733 35,568 10,061 5,899 7,955 71,257
NCL (NCLC) 90,687 0% 4.3 6% 15,931,783 9,700,324 6,385,388 0 973,844 1,432,690 6,107,285

Balance Sheet ($'000)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash1,0021878240562142151522157322802,8471,7772,8502,4241,7411,249722504
Accounts Receivable2419209927451512
Inventory207228264206201222197203141
PP&E447447568570630652654642348192929292917152929
Assets3,8432,9382,9082,7852,6672,5422,543878498104474335322802,98312,88614,43813,46313,21512,07811,30610,821
Accounts Payable10177831121451901782191911591691741711661799196511052518029228314365
Long-Term Debt28
Liabilities1,4661,2671,8782,1622,7831,3341,8412,1982,1162,0832,1652,2142,2852,3542,4392,4931152,6105,6103,1312,9573,5142,9542,8042,151
Stockholders' Equity2,3771,6711,030623-1171,208702-1,320-1,618-1,979-2,118-2,170-2,250-2,351-2,437-2,491-353737,27611,30710,5069,7019,1248,5028,671
Income Statement ($'000)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue12670201135314472058-115-53000
Cost of Revenue8070970259291143430-4300
Gross Profit450114327617916-545-1100
R&D55771006812101411226100009268081,078612485727585
SG&A664752805712677650602467119-24381341410164484690452398410419
Tax-0-0-0-0-0-0-0-0-0-22-282-278-212-130-171-141
Net Income-719-807-1,344-851-792-1,539-645-2,051-296-363-134-43-68-91-76-43-204-634-1,097-1,206-853-751-969-864
Cash Flow ($'000)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-463-988-708-540-459-502-277-47-46-44-317-7-2-75-174-1,405-1,069-1,164-1,011-492-527-218
Cash Investing84-10-2-10-23-100422715-250-2-496476000
Cash Financing-430894668566447524250470150002522,0981090